Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 923120, 8 pages
http://dx.doi.org/10.1155/2014/923120
Research Article

Glucagon-Like Peptide-1 Secreting Cell Function as well as Production of Inflammatory Reactive Oxygen Species Is Differently Regulated by Glycated Serum and High Levels of Glucose

1Department of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, 6 Viale Benedetto XV, 16143 Genoa, Italy
2Division of Cardiology, Department of Medicine, Geneva University Hospitals, Faculty of Medicine, Foundation for Medical Researches, 64 Avenue de la Roseraie, 1211 Geneva, Switzerland
3Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland

Received 22 July 2013; Revised 18 December 2013; Accepted 19 December 2013; Published 4 February 2014

Academic Editor: Eric F. Morand

Copyright © 2014 Alessandra Puddu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Drucker, J. Philippe, S. Mojsov, W. L. Chick, and J. F. Habener, “Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 10, pp. 3434–3438, 1987. View at Google Scholar · View at Scopus
  2. D. J. Drucker and M. A. Nauck, “The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes,” The Lancet, vol. 368, no. 9548, pp. 1696–1705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. J. J. Holst, “The physiology of glucagon-like peptide 1,” Physiological Reviews, vol. 87, no. 4, pp. 1409–1439, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. R. M. Elliott, L. M. Morgan, J. A. Tredger, S. Deacon, J. Wright, and V. Marks, “Glucagon-like peptide-1(7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns,” Journal of Endocrinology, vol. 138, no. 1, pp. 159–166, 1993. View at Google Scholar · View at Scopus
  5. C. Herrmann, R. Goke, G. Richter, H.-C. Fehmann, R. Arnold, and B. Goke, “Glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide plasma levels in response to nutrients,” Digestion, vol. 56, no. 2, pp. 117–126, 1995. View at Google Scholar · View at Scopus
  6. M.-B. Toft-Nielsen, M. B. Damholt, S. Madsbad et al., “Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 8, pp. 3717–3723, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Vollmer, J. J. Hoist, B. Bailer et al., “Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance,” Diabetes, vol. 57, no. 3, pp. 678–687, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Orskov, J. Jeppesen, S. Madsbad, and J. J. Holst, “Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine,” Journal of Clinical Investigation, vol. 87, no. 2, pp. 415–423, 1991. View at Google Scholar · View at Scopus
  9. J. C. Fernandez-Garcia, M. Murri, L. Coin-Araguez, J. Alcaide, R. El Bekay, and F. J. Tinahones, “GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects,” Clinical Endocrinology, 2013. View at Publisher · View at Google Scholar
  10. M. A. Nauck, I. Vardarli, C. F. Deacon, J. J. Holst, and J. J. Meier, “Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?” Diabetologia, vol. 54, no. 1, pp. 10–18, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Rask, T. Olsson, S. Söderberg et al., “Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men,” Diabetes Care, vol. 24, no. 9, pp. 1640–1645, 2001. View at Google Scholar · View at Scopus
  12. E. Rask, T. Olsson, S. Söderberg et al., “Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance,” Metabolism, vol. 53, no. 5, pp. 624–631, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. G. E. Lim, G. J. Huang, N. Flora, D. Leroith, C. J. Rhodes, and P. L. Brubaker, “Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell,” Endocrinology, vol. 150, no. 2, pp. 580–591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Ceriello, M. A. Ihnat, and J. E. Thorpe, “The “Metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications?” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 2, pp. 410–415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Drzewoski, J. Kasznicki, and Z. Trojanowski, “The role of “metabolic memory” in the natural history of diabetes mellitus,” Polskie Archiwum Medycyny Wewnetrznej, vol. 119, no. 7-8, pp. 493–500, 2009. View at Google Scholar · View at Scopus
  16. S. Roy, R. Sala, E. Cagliero, and M. Lorenzi, “Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 1, pp. 404–408, 1990. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Singh, A. Barden, T. Mori, and L. Beilin, “Advanced glycation end-products: a review,” Diabetologia, vol. 44, no. 2, pp. 129–146, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Puddu, R. Sanguineti, A. Durante et al., “Glucagon-like Peptide-1 triggers protective pathways in pancreatic Beta-cells exposed to glycated serum,” Mediators of Inflammation, vol. 2013, Article ID 317120, 10 pages, 2013. View at Publisher · View at Google Scholar
  19. M. Brownlee, “The pathobiology of diabetic complications: a unifying mechanism,” Diabetes, vol. 54, no. 6, pp. 1615–1625, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. P. J. Beisswenger, Z. Makita, T. J. Curphey et al., “Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes,” Diabetes, vol. 44, no. 7, pp. 824–829, 1995. View at Google Scholar · View at Scopus
  21. S. Genuth, W. Sun, P. Cleary et al., “Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes,” Diabetes, vol. 54, no. 11, pp. 3103–3111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Meerwaldt, T. P. Links, R. Graaff et al., “Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy,” Diabetologia, vol. 48, no. 8, pp. 1637–1644, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. M. A. Ihnat, J. E. Thorpe, C. D. Kamat et al., “Reactive oxygen species mediate a cellular “memory” of high glucose stress signalling,” Diabetologia, vol. 50, no. 7, pp. 1523–1531, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Ceriello, “The emerging challenge in diabetes: the, ‘metabolic memory’,” Vascular Pharmacology, vol. 57, pp. 133–138, 2012. View at Publisher · View at Google Scholar
  25. L. Zhang, B. Chen, and L. Tang, “Metabolic memory: mechanisms and implications for diabetic retinopathy,” Diabetes Research and Clinical Practice, vol. 96, pp. 286–293, 2012. View at Publisher · View at Google Scholar
  26. D. J. Drucker, T. Jin, S. L. Asa, T. A. Young, and P. L. Brubaker, “Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line,” Molecular Endocrinology, vol. 8, no. 12, pp. 1646–1655, 1994. View at Google Scholar · View at Scopus
  27. G. Luciano Viviani, A. Puddu, G. Sacchi et al., “Glycated fetal calf serum affects the viability of an insulin-secreting cell line in vitro,” Metabolism, vol. 57, no. 2, pp. 163–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Odetti, J. Fogarty, D. R. Sell, and V. M. Monnier, “Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects,” Diabetes, vol. 41, no. 2, pp. 153–159, 1992. View at Google Scholar · View at Scopus
  29. S. Sugiyama, T. Miyata, Y. Ueda et al., “Plasma levels of pentosidine in diabetic patients: an advanced glycation end product,” Journal of the American Society of Nephrology, vol. 9, no. 9, pp. 1681–1688, 1998. View at Google Scholar · View at Scopus
  30. C. Kappe, J. J. Holst, Q. Zhang, and A. Sjoholm, “Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells,” Biochemical and Biophysical Research Communications, vol. 427, pp. 91–95, 2012. View at Publisher · View at Google Scholar
  31. A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager, “Advanced glycation end products: sparking the development of diabetic vascular injury,” Circulation, vol. 114, no. 6, pp. 597–605, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Niiya, T. Abumiya, S.-I. Yamagishi, J.-I. Takino, and M. Takeuchi, “Advanced glycation end products increase permeability of brain microvascular endothelial cells through reactive oxygen species-induced vascular endothelial growth factor expression,” Journal of Stroke and Cerebrovascular Diseases, vol. 21, no. 4, pp. 293–298, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. T. J. Kieffer and J. F. Habener, “The glucagon-like peptides,” Endocrine Reviews, vol. 20, no. 6, pp. 876–913, 1999. View at Google Scholar · View at Scopus
  34. S. Dhanvantari, A. Izzo, E. Jansen, and P. L. Brubaker, “Coregulation of glucagon-like peptide-1 synthesis with proglucagon and prohormone convertase 1 gene expression in enteroendocrine GLUTag cells,” Endocrinology, vol. 142, no. 1, pp. 37–42, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Némoz-Gaillard, A. Bosshard, R. Regazzi et al., “Expression of SNARE proteins in enteroendocrine cell lines and functional role of tetanus toxin-sensitive proteins in cholecystokinin release,” FEBS Letters, vol. 425, no. 1, pp. 66–70, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Unoki, H. Bujo, S.-I. Yamagishi, M. Takeuchi, T. Imaizumi, and Y. Saito, “Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes,” Diabetes Research and Clinical Practice, vol. 76, no. 2, pp. 236–244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Unoki and S.-I. Yamagishi, “Advanced glycation end products and insulin resistance,” Current Pharmaceutical Design, vol. 14, no. 10, pp. 987–989, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Miele, A. Riboulet, M. A. Maitan et al., “Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism,” Journal of Biological Chemistry, vol. 278, no. 48, pp. 47376–47387, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Cassese, I. Esposito, F. Fiory et al., “In skeletal muscle advanced glycation end products (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for AGEs,” Journal of Biological Chemistry, vol. 283, no. 52, pp. 36088–36099, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. K. D. Kohnert, E. J. Freyse, and E. Salzsieder, “Glycaemic variability and pancreatic beta-cell dysfunction,” Current Diabetes Reviews, vol. 8, pp. 345–354, 2012. View at Publisher · View at Google Scholar
  41. N. Gustavsson and W. Han, “Calcium-sensing beyond neurotransmitters: functions of synaptotagmins in neuroendocrine and endocrine secretion,” Bioscience Reports, vol. 29, no. 4, pp. 245–259, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Reimann and F. M. Gribble, “Glucose-sensing in glucagon-like peptide-1-secreting cells,” Diabetes, vol. 51, no. 9, pp. 2757–2763, 2002. View at Google Scholar · View at Scopus
  43. G. Tolhurst, F. Reimann, and F. M. Gribble, “Nutritional regulation of glucagon-like peptide-1 secretion,” Journal of Physiology, vol. 587, no. 1, pp. 27–32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Ohara-Imaizumi, K. Aoyagi, Y. Akimoto et al., “Imaging exocytosis of single glucagon-like peptide-1 containing granules in a murine enteroendocrine cell line with total internal reflection fluorescent microscopy,” Biochemical and Biophysical Research Communications, vol. 390, no. 1, pp. 16–20, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Somanath, S. Barg, C. Marshall, C. J. Silwood, and M. D. Turner, “High extracellular glucose inhibits exocytosis through disruption of syntaxin 1A-containing lipid rafts,” Biochemical and Biophysical Research Communications, vol. 389, no. 2, pp. 241–246, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. J. M. Gaspar, Á. Castilho, F. I. Baptista, J. Liberal, and A. F. Ambrósio, “Long-term exposure to high glucose induces changes in the content and distribution of some exocytotic proteins in cultured hippocampal neurons,” Neuroscience, vol. 171, no. 4, pp. 981–992, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Puddu, A. Durante, A. Poggi, P. Odetti, and G. L. Viviani, “Glycated serum decreases insulin content and modifies the expression of proteins involved in insulin granule exocytosis,” Diabetes, vol. 54, p. A653, 2005. View at Google Scholar
  48. D. C. Thurmond, “Insulin-regulated glucagon-like peptide-1 release from l cells: actin' out,” Endocrinology, vol. 150, no. 12, pp. 5202–5204, 2009. View at Publisher · View at Google Scholar · View at Scopus